XOMA NEUPREX IN TWO PILOT ANTIBIOTIC ADJUVANT STUDIES FOR RESISTANT BACTERIA
Executive Summary
Xoma is studying its bactericidal/permeability increasing protein Neuprex (rBPI21) in two pilot studies to support use "as an antibiotic adjuvant to conventional antimicrobial interventions," Xoma Chief Scientific & Medical Officer Patrick Scannon, MD/PhD, told FDA's Anti-Infective Drugs Advisory Committee July 25.